NCT04022343View on ClinicalTrials.gov

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

August 6, 2019

Primary Completion Date

February 2, 2022

Study Completion Date

December 9, 2025

Conditions

Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaStage III Renal Cell Cancer AJCC v8

Interventions

DRUG

Cabozantinib

Given PO

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER